CompletedPhase 2
Examining the Effects of Mitochondrial Oxidative Stress in DCM
Key facts
- Who runs it
- Imperial College London
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 53 people enrolled
- Started
- 26 Jul 2022
- Ended
- 19 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MitoQ Compound
- Placebo
- Record updated
- 18 September 2025
Who can take part
- Age
- 16 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- idiopathic or familial DCM
- LVEF ≤45% on 2 imaging studies of any modality ≥3 months apart (may include CMR scan at baseline visit)
- on guideline therapy for ≥3 months as determined by usual clinicians
- sinus rhythm on 12-lead electrocardiogram
- plasma NT-pro-BNP >250ng/L for those >65 years and >100ng/L for those aged ≤65 years within the last 6 months (may include sample at baseline visit)
Who cannot take part
- clear environmental trigger such as excess alcohol intake, cardiotoxic chemotherapy or peripartum presentation
- current cancer (other than non-melanoma skin cancers)
- estimated glomerular filtration rate (eGFR) <30mls/min
- current persistent atrial fibrillation
- contraindication to CMR
- current or planned pregnancy or current breast-feeding
- fibrosis burden >25% on CMR
- current use of CoQ10
- current participation in another randomised controlled trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Double blind, randomised, placebo-controlled trial of MitoQ (mitoquinol mesylate) in 106 patients with dilated cardiomyopathy, examining the effect of reducing mitochondrial oxidative stress on myocardial energetics and myocardial function using 31-phosphorus magnetic resonance spectroscopy and cardiovascular magnetic resonance.
The 2 groups in the trial
- MitoQTreatment being tested
Mitoquinol mesylate 40mg daily
Treatment: MitoQ Compound
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 18 September 2025